ARTICLE | Company News

ArcherDX to develop companion diagnostic for CC-122

December 1, 2017 9:52 PM UTC

ArcherDx Inc. (Boulder, Colo.) will develop and commercialize a companion diagnostic to identify diffuse B cell lymphoma patients who may best respond to CC-122 from Celgene Corp. (NASDAQ:CELG). CC-122 is a cancer pleiotropic pathway modifier in Phase I trials to treat cancer...

BCIQ Company Profiles

ArcherDx Inc.

Celgene Corp.

BCIQ Target Profiles

Cereblon (CRBN)